Research Topics
| Lesley TilsonSummaryAffiliation: St James's Hospital Country: Ireland Publications
|
Detail Information
Publications
Pharmacoeconomic evaluation in Ireland: a review of the processLesley Tilson
National Centre for Pharmacoeconomics, St James s Hospital, James s Street, Dublin 8, Ireland
Pharmacoeconomics 28:307-22. 2010..NCPE recommendations broadly concurred with those of UK agencies for the majority of appraisals...- Cost of care for colorectal cancer in Ireland: a health care payer perspectiveL Tilson
National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
Eur J Health Econ 13:511-24. 2012..Management options for colorectal cancer have expanded in recent years. We estimated average lifetime cost of care for colorectal cancer in Ireland in 2008, from the health care payer perspective... - Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in IrelandL Tilson
National Centre for Pharmacoeconomics, St James Hospital, Dublin 8, Ireland
Vaccine 29:7463-73. 2011..Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective... 
Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluationLesley Tilson
National Centre for Pharmacoeconomics, St James s University Teaching Hospital, James s St, Dublin 8, Ireland
Eur J Public Health 18:275-82. 2008....- Public drug expenditure in the Republic of IrelandMichael Barry
National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
Expert Rev Pharmacoecon Outcomes Res 10:239-45. 2010..Since September 2009, all new pharmaceutical products are considered for pharmacoeconomic assessment. Generic substitution and reference pricing are to be introduced in 2011... - Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims databaseCara Usher
National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
Clin Ther 34:632-9. 2012..In the current national and international economic climate, it is anticipated that demand on these services will continue to grow... - Pricing and reimbursement of drugs in IrelandMichael Barry
National Centre for Pharmacoeconomics, St James s Hospital, 8 Dublin, Ireland
Eur J Health Econ 5:190-4. 2004..Prior to reimbursement under the community drugs schemes, a medicine must be included in the GMS code book or positive list. A demonstration of cost-effectiveness is not a pre-requisite for reimbursement... - A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare settingLaura McCullagh
National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
Pharmacoeconomics 27:829-46. 2009..Rivaroxaban (Xarelto) is a direct factor Xa inhibitor and dabigatran etexilate (Pradaxa) is a prodrug of the active compound dabigatran, which inhibits thrombin... - Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in IrelandLesley Tilson
National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
Value Health 11:898-903. 2008..To evaluate the cost-effectiveness of implementing a universal infant 7-valent pneumococcal conjugate vaccine (PCV7) vaccination program in the Irish health-care setting from the health-care payers' perspective... - The potential impact of implementing a system of generic substitution on the community drug schemes in IrelandLesley Tilson
National Centre for Pharmacoeconomics, Ireland
Eur J Health Econ 6:267-73. 2005..0 million on the GMS and <euro>6.4 million on the DP scheme. Comparison of these results with a similar analysis of 2001 data illustrates the potential for an increase in savings over time... - Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic modelCara Usher
National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
Vaccine 26:5654-61. 2008..This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer... - The high cost of medicines in Ireland. Is it time to change the pricing mechanism?Lesley Tilson
National Centre for Pharmacoeconomics, Dublin, Ireland
Eur J Health Econ 5:341-4. 2004..The estimated savings were statistically significant for the Danish and average European price but not for the UK price. This study demonstrates the high ex-wholesale price of prescription medications in Ireland... - Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010Kathleen Bennett
Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James s Hospital, Dublin, Ireland
Value Health 12:10-5. 2009..Coronary heart disease (CHD) is associated with a large burden of disease in Ireland and is responsible for more than 6000 deaths annually. This study examined the cost-effectiveness of specific CHD treatments in Ireland... - Health Technology Assessment International 7th Annual Meeting: Dublin, Ireland, 6–9 June 2010Emer Fogarty
National Centre for Pharmacoeconomics, St James s Hospital, Dublin, Ireland
Expert Rev Pharmacoecon Outcomes Res 10:501-3. 2010..There was also a lively social program with the conference dinner held at the Guinness Storehouse... - Recent developments in pricing and reimbursement of medicines in IrelandMichael Barry
National Centre for Pharmacoeconomics, St James s Hospital, Dublin 8, Ireland
Expert Rev Pharmacoecon Outcomes Res 7:605-11. 2007..The new Health Information and Quality Authority (HIQA) was established under the Health Act 2007 and will lead the development of Health Technology Assessment (HTA) across the health service...